← Back to scans

Skin cancer vaccine BLA submitted by June 30, 2027?

0x5801ce623a1d2dcb20bec5708fd9f881326aaf1ff82af22248aceccc7bf29708 · Health · 2026-08-20
87%
Agent
86%
Market Price
+0.5%
Edge
65%
Confidence
Volume: 19,647
Spread: 1.0c
Days to resolution: 314
Markets in event: 1
Final Rationale
The decisive fact is that INTerpath-001's pre-planned Phase 3 interim already read out positive on Aug 19, 2026 — over 10 months before the deadline — with both companies publicly committing to file 'within months.' The critique's strongest point (the 2024 FDA rebuff) is weaker than presented: that rejection concerned accelerated approval on randomized Phase 2 data, whereas RFS/DMFS from a positive Phase 3 is a well-precedented basis for full adjuvant-melanoma approval (pembrolizumab, nivolumab were approved on RFS), so waiting for OS maturity is unlikely to be required. CMC complexity for per-patient manufacturing is a genuine slippage risk, but the Marlborough facility has been supplying clinical batches since 2025 and Merck is an experienced co-filer, so the reference-class mismatch mostly affects launch readiness rather than submission timing. The stale 5-8% Monte-Carlo estimate is correctly discounted because its dominant uncertainty term — whether the pivotal trial would succeed and when it would read out — has been resolved. I settle marginally above the thin Polymarket proxy on the strength of the fundamentals, while retaining ~13% for filing slippage past June 2027 or lack of public confirmation before the deadline.
Price vs. prediction
How the market moved after the agent's call. Solid blue line is the actual market price; dashed line is the agent's static forecast at $t{=}0$.
$n = 14$ follow-ups
1. Planner Opus · Fermi decomposition + tool plan
Tools chosen: polymarket_direct claude_news claude_news gdelt_news polymarket_related kalshi_related earnings_data wikipedia code_execution
Sub-questions (Fermi decomposition)
  1. What is the current Polymarket price and recent price history for this market?
  2. What is the expected primary completion / interim analysis timing for the Phase 3 INTerpath-001 trial (NCT05933577) and has any interim readout occurred?
  3. Have Moderna or Merck publicly guided to a BLA filing date or accelerated approval strategy for intismeran autogene, and what regulatory designations (Breakthrough Therapy, RMAT) does it hold?
  4. What is the status of the broader INTerpath program (INTerpath-002 NSCLC, -007, -009) and any recent data readouts or trial setbacks/enrollment issues?
  5. Has Moderna signaled financial/pipeline reprioritization that would delay or accelerate the INT program (e.g., R&D budget cuts, Merck cost-sharing changes)?
  6. What is the historical base rate for an oncology Phase 3 program reaching BLA submission within ~2 years of a given date, given event-driven endpoints?
Planner reasoning
This is a Polymarket question on whether Moderna/Merck submit a BLA for intismeran autogene (mRNA-4157/V940) by June 30, 2027. The key drivers are the Phase 3 INTerpath-001 readout timing (event-driven RFS endpoint), any accelerated approval pathway plans, and company guidance on filing timelines. I'll anchor on the Polymarket price, then research trial timelines, company statements, and cross-venue markets.
2. Research Parallel tool calls
ToolStatusTimeItemsSummary
polymarket_direct OK 0.3s 1 ## This Market's Polymarket Data **Skin cancer vaccine BLA submitted by June 30, 2027?** - Current price (probability): 86.50% - 7-day price change: +0.00% - 30-day price change: +0.00% - Total volume: $19,647 (USD notional) - Price range: 86.50% - 86.50% - Data points: 2 days
claude_news OK 30.8s 15 Based on research, here are the latest findings on intismeran autogene (mRNA-4157/V940): - **Phase 3 INTerpath-001 met primary and key secondary endpoints (Aug 19, 2026):** Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with
claude_news OK 29.0s 10 Based on research, here are the key findings: - **Positive Phase 3 topline results (Aug 19, 2026)**: Merck and Moderna announced the first and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone, and th
gdelt_news OK 155.4s 30 GDELT: 30 articles across 4 queries (lookback=180d). 'intismeran autogene': 10 hits | 'mRNA-4157 Merck Moderna': 10 hits | 'INTerpath-001 melanoma vaccine': error GDELT rate-limited after retries (429) | 'Moderna cancer vaccine BLA FDA': 10 hits
polymarket_related OK 2.2s 0 Scanned 100 active Polymarket markets, kept 0 matches. keyword 'cancer vaccine': 0 markets | keyword 'FDA approval': 0 markets | keyword 'Moderna': 0 markets | keyword 'skin cancer vaccine': 0 markets
kalshi_related OK 2.1s 1 1 related markets / summaries. keyword 'cancer vaccine': no matches | keyword 'FDA approval': ok | keyword 'Moderna': no matches
earnings_data OK 0.2s 2 Fetched FMP data for 2 ticker(s).
wikipedia OK 0.1s 4 Fetched 4 Wikipedia entries (0 missing pages).
code_execution OK 50.5s 0 ## Quantitative Analysis: BLA Submission Probability for Skin Cancer Vaccine (INTerpath-001) by June 30, 2027 **Setup:** Trial completed enrollment (~1,089 patients) mid-2025; primary completion (full RFS event accrual) expected 2029. This leaves only **~24 months** from last-patient-in (LPI) to th
3. Evidence Brief Sonnet · 6146 chars
# Current state Phase 3 INTerpath-001 already delivered a **positive pre-planned interim analysis** on Aug 19, 2026, meeting its primary (RFS) and key secondary (DMFS) endpoints for intismeran autogene + KEYTRUDA in resected stage IIB-IV melanoma. Merck/Moderna have stated intent to "engage with regulators on filing submissions" and file "within months," but as of the latest research (early-mid autumn 2026) **no BLA submission has been officially confirmed** — only pre-submission commitments exist. The market resolves YES only on confirmed submission/acceptance/approval, not on guidance. # Timeline of key events - 2023-02: FDA grants Breakthrough Therapy Designation to mRNA-4157/V940 (confirmed, Wikipedia/FDA). - 2023-04: EMA grants PRIME designation for combo (confirmed). - 2024 (date unspecified): Moderna's earlier bid for accelerated approval rebuffed by FDA (reported, FierceBiotech). - 2025 (mid, ~Sept): Marlborough MA personalized-manufacturing facility begins clinical batch supply, positioned for eventual commercial launch (reported, Yahoo Finance). - 2025-11: Moderna Analyst Day announces ~$0.5B/yr opex cuts (2026-27) toward 2028 cash breakeven; oncology/intismeran still prioritized (confirmed, SEC/AccessNewswire). - 2026-05-01: Moderna Q1 earnings confirm nine active INT trials, new Stage I NSCLC monotherapy Phase 3 initiated (confirmed, SEC 8-K). - 2026-06-02/03: 5-year melanoma survival data presented (ASCO), ~49% reduced recurrence (confirmed, Merck.com/press). - 2026-08-19: INTerpath-001 interim analysis positive — met primary/key secondary endpoints; companies signal regulatory engagement and filing "within months," no firm date given (confirmed, Merck/Moderna PR, CNN, FierceBiotech). Trial continues for OS. - Post-Aug 2026: No confirmed BLA submission announcement found in research to date. # Event Will Moderna/Merck submit (or FDA accept/approve) a BLA for intismeran autogene by June 30, 2027? # Outcomes to forecast Yes / No # Kalshi market anchor **Kalshi direct YES price was not returned in the research** (only unrelated kalshi_related markets — VERVE-102 50%, Type 1 diabetes cure 42%, MDMA/PTSD 56% — surfaced, none matching this ticker). No Kalshi-specific volume/trend data available. Treat this as a genuine gap; use Polymarket as best cross-market proxy. # Sub-question answers 1. **Polymarket price/history** — 86.5% YES, flat 7d/30d trend, only 2 days of data, low volume ($19.6k) — market appears newly listed, likely post-Aug 19 readout (Polymarket direct). 2. **INTerpath-001 timing/interim** — Pre-planned interim analysis reported positive Aug 19, 2026, meeting primary (RFS) and key secondary (DMFS) endpoints; trial continues for OS (Merck/Moderna PR, FierceBiotech). 3. **Filing guidance/designations** — No firm filing date; companies say submission "within months" of Aug 2026 readout. BTD (FDA, 2023) and PRIME (EMA, 2023) both still held. Prior 2024 accelerated-approval attempt was rejected by FDA (FierceBiotech). 4. **Broader INTerpath program** — 9 trials active (melanoma, NSCLC, bladder, RCC); melanoma Ph3 and RCC Ph2 fully enrolled; NSCLC Ph3 studies (incl. new Stage I monotherapy trial started 2026) still enrolling; no reported setbacks (Merck.com, SEC 8-K). 5. **Financial/pipeline reprioritization** — Nov 2025 Analyst Day cut opex ~$0.5B/yr (2026-27) toward 2028 breakeven, but Bancel reaffirmed oncology/intismeran as core priority; no signal of INT deprioritization (SEC 10-Q, AccessNewswire). 6. **Base rate for Ph3→BLA within ~2yrs** — Comparable gene/cell-therapy BLAs (e.g., Intellia lonvo-z) filed ~6-9 months post-positive-data. A Monte-Carlo model (code_execution) built pre-readout assumptions and estimated only 5-8% central probability — but that model is now **stale/superseded**: it assumed the interim hadn't yet occurred, whereas it has already read out positive as of Aug 19, 2026, materially compressing remaining uncertainty. # Key facts (high-confidence, factual) 1. [Merck/Moderna PR, Aug 19 2026] INTerpath-001 interim met primary/secondary endpoints. 2. [CNN] Companies plan to file "within months," no specific date given. 3. [FierceBiotech] 2024 accelerated-approval request was previously rejected by FDA. 4. [Wikipedia/FDA] BTD granted Feb 2023, still active; EMA PRIME April 2023. 5. [SEC 10-Q/8-K] Nine active INT trials; program not deprioritized despite cost cuts. 6. [Polymarket] Current YES price 86.5%, thin/new market. # Cross-market signals - Kalshi (this market): price unavailable in research (gap). - Kalshi related FDA-approval markets: 42-56% range (different drugs, not directly comparable). - Polymarket: 86.5% YES — strongly bullish, but low liquidity/short history. # Analyst opinions and speculation - Oncologist (travelerstoday.com): expects approval/access "early 2027," implying submission likely by late 2026. - Analysts (BioSpace): market launch possible "as early as 2027" but meaningful sales more likely 2028 — suggests filing could still occur well before mid-2027. - top1markets.com: cautions no explicit filing timeline exists; Moderna won't book 2026/2027 intismeran revenue — modest bearish counterpoint. # Directional lean per outcome - **Yes**: Positive interim already announced; BTD/PRIME could accelerate filing; manufacturing facility operational; analysts see 2027 launch as plausible; Polymarket strongly favors Yes (86.5%). - **No**: No firm filing date announced; personalized-neoantigen CMC complexity could delay filing beyond mid-2027; prior 2024 FDA rejection shows regulatory friction; "within months" is vague and could slip past June 2027. # Gaps / unknowns - No Kalshi-direct price/volume data retrieved for this ticker — critical anchor missing. - No confirmed BLA submission date or FDA rolling-review acceptance found. - Unclear whether "within months" (stated Aug 2026) means Q4 2026 or later 2027. # Calibration anchors - Kalshi YES price: unavailable (gap) — use Polymarket 86.5% as best available consensus proxy. - Precedent: Intellia lonvo-z filed ~6-9 months post-positive-data — analogous timeline would place intismeran BLA around Q1-Q2 2027, before deadline.
4. Forecasters Opus + GPT · in parallel
claude-opus-5
0.62
Yes 88%
No 12%
The Phase 3 INTerpath-001 interim readout was positive on Aug 19, 2026 — nearly a year before the June 30, 2027 deadline — and Merck/Moderna publicly committed to regulatory filing 'within months,' backed by FDA Breakthrough Therapy designation, EMA PRIME, and an operational Marlborough personalized-manufacturing site. Comparable precedents (e.g., Intellia lonvo-z) show ~6-9 months from positive pivotal data to BLA, which lands squarely in Q1-Q2 2027. Polymarket, the only available consensus proxy (Kalshi price was a research gap), sits at 86.5% YES despite thin liquidity. Residual risk comes from personalized-neoantigen CMC complexity, the vagueness of 'within months,' the prior 2024 FDA rebuff of accelerated approval, and the possibility that a submission occurs but isn't publicly confirmed before the deadline — hence a modest discount below certainty.
gpt-5.5
0.68
Yes 84%
No 16%
With no Kalshi-direct price available, I anchor on the best proxy, Polymarket at 86.5% YES, while noting it is thin and newly listed. The positive pre-planned INTerpath-001 interim readout meeting RFS and DMFS points toward Yes because it removes the largest clinical uncertainty and the companies explicitly said they plan regulatory submissions “within months.” Breakthrough Therapy/PRIME designations, active manufacturing preparation, and continued prioritization of intismeran also point toward Yes because they reduce procedural and strategic delay risk. The main reasons to shade slightly below the 86.5% proxy are the absence of a confirmed filing date, personalized-vaccine CMC complexity, and the prior FDA rejection of an accelerated-approval attempt, all of which leave a meaningful chance of slippage beyond June 30, 2027.
5. Devil's Advocate Sonnet · red-team critique
1. Both forecasts lean almost entirely on the Polymarket 86.5% figure despite the brief's own caution that it's "only 2 days of data, low volume ($19.6k)... likely post-Aug 19 readout" — a thin, newly-formed market shouldn't be treated as a robust consensus anchor, yet both forecasts land within 4 points of it (0.84/0.88), suggesting anchoring/herding rather than independent synthesis. 2. Neither forecast grapples with the fact that the 2024 FDA rejection of accelerated approval was for this *same* drug/indication (not just a generic comparator), which is a much stronger negative signal than "regulatory friction in general" — it implies FDA already signaled the RFS/DMFS interim data may not suffice for an early filing, potentially pushing the timeline toward waiting for OS data (which the brief notes the trial "continues" to collect), a scenario that could easily push submission past June 2027. 3. Both dismiss the Monte-Carlo model's 5-8% estimate as "stale/superseded" without engaging its underlying logic (personalized-neoantigen CMC complexity, novel-modality manufacturing/QC burdens) — they should explain *why* the positive interim compresses that gap by 10x rather than treating the older estimate as simply irrelevant. 4. The base-rate precedent (Intellia lonvo-z, ~6-9 months from data to BLA) is a gene-editing therapy, not a personalized neoantigen mRNA vaccine requiring per-patient manufacturing — this is a reference-class mismatch that both forecasts adopt uncritically as their central timing anchor. 5. Neither forecast separately weights the two distinct pathways to YES — (a) an early accelerated-approval-style filing based on interim RFS/DMFS vs. (b) a full BLA after OS maturity — and how the 2024 rejection specifically forecloses path (a), which materially changes the probability calculus versus treating "submission" as a single undifferentiated event. 6. Both forecasts fail to flag the Kalshi-price gap as a major uncertainty driver in their final confidence levels (0.62, 0.68) — given the explicit absence of the actual market being forecast and reliance on a proxy market for a *different* platform's audience/liquidity dynamics, confidence should arguably be lower or a wider probability band considered.
6. Aggregator Opus · final calibrated forecast
87% (65% confidence)
Yes: 87% No: 13%
The decisive fact is that INTerpath-001's pre-planned Phase 3 interim already read out positive on Aug 19, 2026 — over 10 months before the deadline — with both companies publicly committing to file 'within months.' The critique's strongest point (the 2024 FDA rebuff) is weaker than presented: that rejection concerned accelerated approval on randomized Phase 2 data, whereas RFS/DMFS from a positive Phase 3 is a well-precedented basis for full adjuvant-melanoma approval (pembrolizumab, nivolumab were approved on RFS), so waiting for OS maturity is unlikely to be required. CMC complexity for per-patient manufacturing is a genuine slippage risk, but the Marlborough facility has been supplying clinical batches since 2025 and Merck is an experienced co-filer, so the reference-class mismatch mostly affects launch readiness rather than submission timing. The stale 5-8% Monte-Carlo estimate is correctly discounted because its dominant uncertainty term — whether the pivotal trial would succeed and when it would read out — has been resolved. I settle marginally above the thin Polymarket proxy on the strength of the fundamentals, while retaining ~13% for filing slippage past June 2027 or lack of public confirmation before the deadline.
Pipeline Timing
Total pipeline time: 270.1s
Per-tool research timings shown in the Research section above.